Zoetis

Open: 196.0 Close: 194.66 Change: -1.34

7 risks of investing in Zoetis Company Inc Stock found by an AI after reading the whole internet.

The game is changing. There is a new strategy to evaluate Zoetis fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Zoetis are: Zoetis, market, share, report, earnings, test, NYSEZTS, and the …

Concept Map

Semantic Network

Stock Summary

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products. Zoetes offers products primarily across species, including livestock, such as cattle, swine, poultry, fish,.

Today's Summary

Zoetis Services and IDEXX Labs accounted for more than 40% of the global veterinary rapid test kits market share. Company generated revenue of $8.1 billion in 2022 with approximately 13,800 employees.

Today's News

Zoetis Inc. has gained 47% since 2019 primarily due to favorable change in revenues. The company generated revenue of $8.1 billion in 2022 with approximately 13,800 employees. Investors and other interested parties will be able to access a live audio webcast of the presentation. Zoetis Services and IDEXX Labs accounted for more than 40% of the global veterinary rapid test kits market share. The leading market players offer a comprehensive range of tests for heartworm, feline leukemia, and other diseases. Zoetis (NYSE:ZTS) has outperformed the market over the past 5 years by 3.99% on an annualized basis producing an average annual return of 15.54% Currently, Zoetiss has a market capitalization of $83.2. Zoetis reported earnings of $1.36 per share, beating the Zacks Consensus Estimate of $ 1.35 per share. For their last quarter, Zoetas (ZTS) reported earnings. Ground Jury named for eventing at the 2024 Paris Olympics. 28 pairs and horses are already identified by the federal sports management team and accompanied by the FFE both on the sport side and on the horse. Electro Mechanical Technician - 3rd Shift 11:00pm - 7:30am role at Zoetis. Be among the first 25 applicants See who Zoetes has hired for this role. Analysts at Zacks Research raised their FY2024 earnings per share (EPS) estimates for Zoetis in a report issued on Tuesday, December 12th. The consensus estimate is $5.41 per share. The firm also recently announced a quarterly dividend, which will be paid on March 1st. Zoetis CEO Kristin Peck, Chief Executive Officer, sold US$182.88K in Common Stocks on Dec 18, 2023 at an average price of $198.14 for a total value of $182.87K. Zoetiss (NYSE:ZTS) short percent of float has risen 10.61%. Zoetis develops, markets, and sells products related to eight species of companion and food animals. Companion animals are now their largest sector.

Stock Profile

"Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. The company also offers parasiticides; vaccines; anti-infectives; other pharmaceutical products; dermatology; and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products and laboratory; and other non-pharmaceutical products. It markets its products to veterinarians, livestock producers, and pet owners. The company was founded in 1952 and is headquartered in Parsippany, New Jersey."

Keywords

This document will help you to evaluate Zoetis without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Zoetis are: Zoetis, market, share, report, earnings, test, NYSEZTS, and the most common words in the summary are: zoetis, stock, x, news, market, share, dividend, . One of the sentences in the summary was: Company generated revenue of $8.1 billion in 2022 with approximately 13,800 employees.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #zoetis #stock #x #news #market #share #dividend.